JMS-17-2 is a potent and selective CX3CR1 antagonist with IC50 of 0.32 nM. JMS-17-2 can impairs metastatic seeding and colonization of breast cancer cells.
In vivo, JMS-17-2 (10 mg/kg; i.p.; twice a day for three weeks) causes a dramatic reduction of tumors in both skeleton and visceral organs in SCID mice.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO ≥ 10 mg/mL|
|Storage||2-8°C, protect from light, dry, sealed|
|Related CXCR Products|
SRT3190 is an antagonist of CXCR2 that can be used in chemokine-mediated disease studies.
LY2510924 is a potent and selective CXCR4 antagonist, which blocks SDF-1 binding to CXCR4 with IC50 of 0.079 nM.
Motixafortide (BL-8040) is an antagonist of CXCR4 with IC50 value of 1 nM.
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4).
SX-682 is a potent and selective CXCR1/2 allosteric inhibitor, it may be useful for castration-resistant prostate cancer.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.